Study results suggest that flotetuzumab demonstrates antileukemic activity in patients with primary induction failure and early-relapse acute myeloid leukemia.
A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
Investigators retrospectively assessed whether previous TKI therapy may affect response and survival outcomes in patients with relapsed or refractory acute myeloid leukemia.
The bispecific CAR-T therapy targets CD20 and CD19.
Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.
A CAR-T therapy for myeloma that is manufactured using a unique process showed clinical activity and appeared safe, even in the outpatient setting.
A fully human BCMA-directed CAR-T product showed clinical activity in patients with relapsed/refractory multiple myeloma.
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.